Koichi Goto
Kashiwa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 314 publications
DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.
Journal: Future oncology (London, England)
Published: September 02, 2026
Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.
Journal: Targeted oncology
Published: June 30, 2026
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 31, 2026
Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 23, 2026
Enhanced Therapeutic Efficacy of Photodynamic Therapy Using Hybrid Liposomes Containing Indocyanine Green in a Triple-Negative Breast Cancer Mouse Model.
Journal: Biological & pharmaceutical bulletin
Published: February 15, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 05, 2026
Development of machine learning models to determine CO2 seepage in the ocean based on the seepage and non-seepage database.
Journal: Marine pollution bulletin
Published: February 01, 2026
VEGF-A splicing variant in plasma is a predictive potential biomarker of bevacizumab in advanced non-squamous non-small cell lung cancer.
Journal: Journal of chemotherapy (Florence, Italy)
Published: December 27, 2025
Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.
Journal: Targeted oncology
Published: December 19, 2025
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.
Journal: JAMA network open
Published: November 12, 2025
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: October 17, 2025
Last Updated: 09/26/2026